| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(1 year, 8 months ago) | |
|
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(1 year, 2 months ago) | |
| US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(2 years from now) | |
|
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(2 years from now) | |
Zetia is owned by Organon.
Zetia contains Ezetimibe.
Zetia has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zetia are:
- US7030106
- US7030106*PED
Zetia was authorised for market use on 25 October, 2002.
Zetia is available in tablet;oral dosage forms.
Zetia can be used as to reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; reduction of elevated plasma sterol and/or stanol levels in a mammal.
The generics of Zetia are possible to be released after 30 April, 2026.
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...
Dosage: TABLET;ORAL
ZETIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic